

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5381365

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	OREXO AB	01/30/2019
RECEIVING PARTY DATA		
Name:	GESYNTA PHARMA AB	
Street Address:	FOGDEVRETEN 2	
City:	SOLNA	
State/Country:	SWEDEN	
Postal Code:	SE-171 65	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Patent Number:	8759537
CORRESPONDENCE DATA		
Fax Number:		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	949 253-0900	
Email:	ocpatents@klgates.com	
Correspondent Name:	K&L GATES LLP	
Address Line 1:	1 PARK PLAZA	
Address Line 2:	TWELFTH FLOOR	
Address Line 4:	IRVINE, CALIFORNIA 92614	
ATTORNEY DOCKET NUMBER:	1958449.00001	
NAME OF SUBMITTER:	DOROTHY L. CHAMBERS	
SIGNATURE:	/DOROTHY L. CHAMBERS/	
DATE SIGNED:	02/19/2019	
Total Attachments: 3		
source=Assignment Orexo AB to Gesynta Pharma AB#page1.tif		
source=Assignment Orexo AB to Gesynta Pharma AB#page2.tif		
source=Assignment Orexo AB to Gesynta Pharma AB#page3.tif		

CONFIRMATORY ASSIGNMENT

THIS ASSIGNMENT is made the 30th day of January 2019

BETWEEN:-

- (1) Orexo AB of Box 303, SE-751 05 Uppsala, Sweden (the "Assignor"); and
- (2) Gesynta Pharma AB of Fogdevreten 2, SE-171 65 Solna, Sweden (the "Assignee").

BACKGROUND:-

- (A) The Assignor is the registered proprietor and beneficial owner of the patent matters set out in the schedule to this Assignment (the "Patents").
- (B) By an Asset Purchase Agreement dated 29 September 2017 between the Assignor and the Assignee (the "Agreement") the parties have agreed that the Assignor's rights in the Patents should be transferred by the Assignor to the Assignee on the terms set out below.

IT IS AGREED THAT:

- 1 Pursuant to the Agreement and for the consideration stated in the Agreement the Assignor ASSIGNS with full title guarantee absolutely and free from any licences, charges or other encumbrances:-
 - a. all right, title and interest in and to the Patents TOGETHER WITH all rights and powers arising or accrued from the Patents including the right to sue for damages and other remedies in respect of any infringement of such rights or other acts within the scope of the claims of any published specifications of the Patents prior to the date of this Assignment; and
 - b. the right to apply for, prosecute and obtain patent or similar protection throughout the world in respect of the inventions (the "Inventions") claimed in the Patents including the right to claim priority from the Patents to the intent that the resulting grant of any patents or similar protection shall be in the name of and vest in the Assignee.
- 2 This Assignment will be governed by and construed in accordance with the laws of Sweden without regard to any choice of law principle that would dictate the application of the law of another jurisdiction. Any dispute or claim arising out of or in connection with this Assignment will be subject to and resolved in accordance with the Dispute Resolution provisions in the Agreement.

SCHEDULE

The Patents


Proprietor	Patent number	Country
Orexo AB	EP 2 606 036	AL, AT, BA, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, ME, RS
Orexo AB	2011290725	Australia
Orexo AB	112013003753-9	Brazil
Orexo AB	2804575	Canada
Orexo AB	ZL201180039690.6	China
Orexo AB	021433	Eurasia
Orexo AB	1180312	Hong Kong
Orexo AB	223466	Israel
Orexo AB	1564/DELNP/2013	India
Orexo AB	5650844	Japan
Orexo AB	10-1891494	Korea
Orexo AB	MX/a/2013/001929	Mexico
Orexo AB	706730	New Zealand
Orexo AB	8759537	U.S.A.

IN WITNESS of these matters this document has been executed by the parties on the date set out at the beginning of this Assignment.

Signed by

for and on behalf of

Orexo AB


) 
) Robert Rön
) VP, Head of R&D
) Uppsala 30 Jan 2019

Witnessed by

Name

Signature


Address

) Ylva Almqvist
) 
) Torbjörnsg. 9
) 753 35 Uppsala
) Sweden

Signed by

for and on behalf of

Gesynta Pharma AB

) 
) Patrik Stenberg
) CEO
) Solna February 4th 2019